A flat start to the week as global markets remain mixed

Published 20-JUL-2020 09:21 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The S&P/ASX 200 index (XJO) closed at 6033 points on Friday, up 114 points or 1.9% on a week on week basis following a particularly strong performance from the mining sector and a rebound in interest in the big four banks.

However, Friday’s gain of approximately 0.4% or 23 points was relatively moderate, and is fairly insignificant in terms of providing a lead as to how our markets will perform in the coming week.

Similarly, overseas markets were mixed at the end of last week, offering little direction as to how our markets will trade on Monday.

With scant macroeconomic data emerging this week we could see a significant focus on COVID progress, whether it be in the form of new cases or on a brighter note new vaccines.

The other key market moving news will stem from our politicians who will be providing a rundown on the state of the economy, as well as updating revisions to stimulus and assistance packages such as lending for small business, and JobKeeper and JobSeeker allowances.

While the allowances are expected to be extended until December at this stage, they could be on a scaled-down basis, a move that would likely reduce consumer spending, putting more pressure on businesses.

While there was some promising news towards the end of last week regarding trials, the likelihood of any near-term rollout of vaccinations remains extremely slim.

The ASX SPI200 futures index reflects the degree of uncertainty that prevails as we kick off a new week, up only two points to 6004 points.

24 hours

Markets in the Asia-Pacific region were mixed on Friday with the Hang Seng gaining 0.5% to close at 118 points while the Nikkei 225 closed down 0.3% at 22,696 points.

The Shanghai Composite finished slightly up at 3214 points.

The FTSE 100 was the best performing index in that region, gaining 40 points or 0.6% to close at 6290 points.

The DAX gained 0.3% as it pushed through the 12,900 point mark, edging its way towards 13,000 points which was broadly in line with where the index was before it hit the coronavirus cliff.

The CAC 40 shed 0.3% to close at 5069 points.

As has often been the case in the US, markets were mixed with the Dow down 0.2% to 26,671 points, while the NASDAQ gained 0.3% to push just above the 10,500 point mark.

The S&P 500 gained 0.3%, closing at 3224 points.

On the commodities front, gold finished the week strongly, closing at US$1812 per ounce after dipping below US$1800 per ounce on Thursday.

After an erratic week, the Brent Crude Oil Continuous Contract finished at US$43.14 per barrel, broadly in line with where it started the week.

Following three consecutive days of nominal declines, the copper rally may have commenced again as it finished the week at US$2.93 per pound.

It was a different story for nickel, zinc and lead as those metals all trended south on Friday.

The Australian dollar broke through the US$0.70 mark on Wednesday but retraced slightly on Thursday before finishing the week close to US$0.70 after a strong rally late in the piece on Friday.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X